Pancreatic VIPoma visualized by 68Ga DOTA-NOC PET-CT

Nuklearmedizin 2015; 54(04): N32-N33
DOI: 10.1055/s-0037-1616615

Case report

Schattauer GmbH

Pancreatic VIPoma visualized by ⁶⁸Ga DOTA-NOC PET-CT

I. Wimmer

¹University Hospital St. Pölten, Austria

,

G. Minear

¹University Hospital St. Pölten, Austria

,

R. Brustbauer

¹University Hospital St. Pölten, Austria

,

P. Götzinger

¹University Hospital St. Pölten, Austria

,

K. Dam

¹University Hospital St. Pölten, Austria

References
1 Ro C, Chai W, Yu VE, Yu R. Pancreatic neuroendocrine tumors: biology, diagnosis and treatment. Chin J Cancer 2013; 32: 312-324.
2 Balachandran A, Tamm EP, Bhosale PR. et al. Pancreatic neuroendocrine neoplasms: diagnosis and management. Abdom Imaging 2013; 38: 342-357.
3 Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol 2012; 26: 737-753.
4 Camera L, Severino R, Faggiano A. et al. Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma. World J Radiol 2014; 6: 840-845.
5 Imeriale A, Rust E, Gabriel S. et al. ¹⁸F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. J Nucl Med 2014; 55: 367-372.
6 Hartmann H, Freudenberg R, Oehme L. et al. Dosimetric measurements of 68Ga-high affinity DOTATATE: twins in spirit part III. Nuklearmedizin 2014; 53: 211-216.